19
NOV
2018

Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma

Posted By :
Comments : Off
Presented at Society for Neuro-Oncology Conference Data Continuing to Mature, Particularly Regarding Long Tail of Survival Curve BETHESDA, Md., November 19, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer were presented...
Read More
13
NOV
2018

NW Bio Announces $5 Million Bridge Funding

Posted By :
Comments : Off
Notes With 50% Warrants Exercisable at $0.35 Per Share BETHESDA, Md., November 13, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on November 7, 2018, it completed an aggregate financing of $5 million from long term angel investors. The notes have a one-year maturity, subject to the Company’s right to prepay the...
Read More
28
AUG
2018

NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit

Posted By :
Comments : Off
BETHESDA, Md., August 28, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio is presenting at 8:00 pm Wednesday evening, August 29, at the Immuno-Oncology Summit being held at the Seaport World Trade Center, 1 Seaport Boulevard in Boston, Massachusetts. The title...
Read More
31
MAY
2018

NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

Posted By :
Comments : Off
BETHESDA, Md., May 31, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will...
Read More
29
MAY
2018

NW Bio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

Posted By :
Comments : Off
Median survival of top 100 patients is 40.5 months, Median survival of all 331 patients is 23.1 months, Longest survivors have exceeded 7 years BETHESDA, Md., May 29, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L...
Read More